Research use only. TB-500 (thymosin beta-4) is supplied strictly for in vitro laboratory research and is not for human or veterinary use, food, or drug applications.
Thymosin beta-4 (Tβ4) is among the most abundant small peptides in mammalian cells, and it is one of the few whose primary biochemical function has been characterized in unusual detail: it binds monomeric actin. That single property — sequestration of the globular (G-actin) pool — anchors most of the mechanistic literature, and it is the reason the peptide appears so often in cytoskeletal and cell-migration research. This overview summarizes what the preclinical record describes about structure, actin binding, migration assays, and the study contexts in which Tβ4 has been examined.
Reviewed for research accuracy: July 30, 2026
What the TB-500 designation actually refers to
“TB-500” is a supply-chain designation rather than a formal pharmacological name, and the distinction matters for experimental design. Material offered under that label is most often a short synthetic peptide corresponding to the actin-binding region of Tβ4 — commonly the acetylated sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ) — whereas the large majority of peer-reviewed studies the designation borrows from were performed with full-length, 43-residue thymosin beta-4.
The two are not interchangeable in a research setting. A fragment containing the binding motif can reproduce some actin-related behavior in vitro, but full-length Tβ4 carries additional sequence implicated in extracellular signaling and in generating downstream fragments. Researchers should confirm from the certificate of analysis which sequence and molecular weight they are actually working with before mapping their results onto published findings.
Structure and the LKKTET motif
Full-length Tβ4 is a 43-amino-acid, strongly acidic peptide of roughly 4.9 kDa. In free solution it is largely unstructured — an intrinsically disordered peptide — and studies indicate it adopts partial helical character upon binding actin. The central hexapeptide motif LKKTET, located around residues 17–22, is conserved across the β-thymosin family and has been identified in structural and mutagenesis work as essential to the actin interaction. Sequences marketed under the TB-500 designation are built around this motif.
Actin sequestration: the primary characterized mechanism
Tβ4 was originally isolated as the cytosolic factor responsible for maintaining a large pool of unpolymerized actin. It binds G-actin in an approximately 1:1 complex with reported affinities in the low micromolar range, and the bound monomer is inhibited from adding to filament ends. Functionally, this makes Tβ4 a buffer on the monomer–filament equilibrium rather than an active remodeler.
That places it in a distinct category from other actin-binding proteins studied alongside it:
- Profilin also binds monomers but delivers them to barbed filament ends, promoting elongation rather than withholding it.
- Gelsolin and cofilin act on filaments — severing and, in cofilin’s case, accelerating depolymerization.
- Tβ4 holds monomers in reserve, and research suggests the size of that reserve influences how quickly a cell can mount localized polymerization.
Because the sequestered pool can be released as free monomer concentration drops, the model that emerges from in vitro work is one of a rapidly mobilizable actin store — a plausible mechanistic bridge between Tβ4 levels and the cytoskeletal reorganization that precedes cell movement.
Cell migration research
Migration is where Tβ4 has been examined most consistently. In cultured endothelial cells, preclinical studies have reported increased directional migration in Boyden-chamber and scratch-closure assays following exposure to the peptide. Comparable migration readouts have been described in keratinocyte and corneal epithelial models, where investigators have also examined changes in cell-matrix adhesion components such as laminin-5.
Signaling work has looked beyond the cytoskeleton itself. In a widely cited cardiac cell study, Tβ4 was reported to associate with integrin-linked kinase (ILK) and downstream Akt phosphorylation, and the observed migratory effects were attenuated when that pathway was disrupted — evidence that at least part of the phenotype in those models is signaling-mediated rather than a direct consequence of monomer sequestration. These findings are from animal and cell-culture systems; they have not been established in humans.
Extracellular behavior and the Ac-SDKP fragment
Tβ4 lacks a classical secretion signal sequence, yet extracellular peptide has been detected in wound fluid and plasma in animal studies, and non-classical release has been proposed. No definitive high-affinity receptor for extracellular Tβ4 has been established, which remains one of the notable gaps in the mechanistic account.
A related line of research concerns Ac-SDKP (N-acetyl-Ser-Asp-Lys-Pro), an N-terminal tetrapeptide that prolyl oligopeptidase can liberate from Tβ4. Ac-SDKP has been studied independently in angiogenesis and fibrosis models, meaning some effects attributed to full-length Tβ4 in vivo may reflect the activity of this cleavage product. A fragment such as Ac-LKKTETQ cannot generate it — another reason sequence identity should be verified before comparing results across studies.
Study contexts at a glance
| Entity | Composition | Characterized in research as | Study-design note |
|---|---|---|---|
| Thymosin beta-4 (Tβ4) | 43 residues, ~4.9 kDa, acidic, intrinsically disordered | Principal G-actin sequestering peptide; examined in migration, angiogenesis, and inflammatory-signaling models | The form used in most primary literature |
| TB-500 (as commonly supplied) | Short acetylated fragment around the LKKTET motif (often Ac-LKKTETQ) | Retains the actin-binding motif; less thoroughly characterized than the parent peptide | Confirm sequence and MW on the COA before citing Tβ4 data |
| Ac-SDKP | N-terminal tetrapeptide released by prolyl oligopeptidase | Studied separately in angiogenesis and fibrosis models | Cannot be generated from a C-terminal-region fragment |
Laboratory handling and preparation arithmetic
Both the full-length peptide and its short fragments are highly water-soluble owing to their acidic character, and are typically supplied lyophilized. Standard practice for lyophilized research peptides applies: store the sealed vial cold and protected from light, allow it to reach room temperature before opening to limit condensation, reconstitute gently down the vial wall without vortexing, and aliquot to avoid repeated freeze–thaw cycles of the stock.
Concentration arithmetic for preparing stock solutions is straightforward. A 5 mg lyophilate brought up in 2 mL of diluent yields a 2.5 mg/mL stock; 100 µL of that stock therefore contains 250 µg of peptide. The reconstitution calculator handles the same arithmetic for other vial sizes and target working concentrations. This is laboratory dilution math for preparing in vitro stocks only.
For assay work, purity and identity data matter more than nominal label strength. HPLC purity, mass-spectrometric confirmation of the expected molecular weight, and — for any cell-based system — endotoxin status are the parameters most likely to explain irreproducible migration results between labs.
Limitations in the current literature
Several caveats recur across reviews. The overwhelming majority of published findings come from cell-culture and rodent models, and human data remain limited. Extracellular signaling is described phenomenologically because no receptor has been definitively identified. Reported effects vary substantially with model system, peptide form, and concentration range. And the fragment-versus-full-length distinction is frequently blurred in secondary sources, which propagates comparisons that the primary literature does not support. Researchers designing new work should specify which construct they are using and cite primary studies performed with that same construct.
References
- Huff T, Müller CS, Otto AM, Netzker R, Hannappel E. Int J Biochem Cell Biol. 2001;33(3):205–220. PMID: 11311852. (Review of β-thymosin structure and actin-sequestering function.)
- Goldstein AL, Hannappel E, Kleinman HK. Trends Mol Med. 2005;11(9):421–429. PMID: 16099219.
- Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Nature. 2004;432(7016):466–472. PMID: 15565145. (ILK/Akt signaling and cell migration in cardiac models.)
- Safer D, Elzinga M, Nachmias VT. J Biol Chem. 1991. (Identification of thymosin β4 as the actin-sequestering factor previously designated Fx.)
- Malinda KM, Goldstein AL, Kleinman HK. FASEB J. 1997. (Directional migration of human umbilical vein endothelial cells in vitro.)
- Sosne G and colleagues, corneal epithelial migration and inflammatory-marker studies in animal and cell-culture models, Experimental Eye Research and Experimental Cell Research, 2002–2010.
- Preclinical investigations of Ac-SDKP, the N-terminal tetrapeptide released from Tβ4 by prolyl oligopeptidase, in angiogenesis and fibrosis models (multiple groups; summarized in β-thymosin review volumes of Annals of the New York Academy of Sciences).
Note on citations: verbatim article titles are omitted where a title contains clinical-outcome language. Authors, journal, year, and PMID resolve each record. No identifier here is approximated — where a specific PMID could not be confirmed, the finding is cited by author, journal, and year only.
Research use only. The information above summarizes published preclinical literature for laboratory reference and makes no therapeutic, diagnostic, or performance claim. TB-500 (thymosin beta-4) is not for human or veterinary use, food, or drug applications.